U.S., Jan. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07322237) titled 'DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis' on Nov. 30, 2025.
Brief Summary: 1. This proposed double-blind placebo controlled randomized controlled trial incorporates recent advances in management of heart failure and portal hypertension using the SGLT-2 inhibitor i.e. EMPAGLIFLOZIN. The drug has been found to be useful in large trials on heart failure with preserved ejection fraction in the general population with improvement in MASLD progression, with improvement in body weight and hepatic steatosis but no change in liver fibrosis.
2. Sodium-glucose cotransporter 2 (SGLT2) inhibito...